Home > Inhibitors & Agonists > Tyrosine Kinase > Syk
Cat. No. Product name CAS No.
DC9632 BAY 61-3606 (dihydrochloride) Featured

BAY 61-3606 2Hcl is a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase activity (Ki= 7.5 nM) with no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src.

648903-57-5
DC10660 BAY 61-3606 free base Featured

BAY 61-3606 is a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase activity (Ki= 7.5 nM) with no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src.

732983-37-8
DC7948 PRT-060318(PRT318) Featured

PRT-060318 is a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model.

1194961-19-7
DC1014 R406 free base Featured

R406 is a potent Syk inhibitor with IC50 of 41 nM and also potently inhibits Flt3.

841290-80-0
DC8733 R406 Featured

R406 is a potent Syk inhibitor with IC50 of 41 nM and also potently inhibits Flt3.

841290-81-1
DC9841 Fostamatinib(R788) Featured

R788 (Fostamatinib), a prodrug of the active metabolite R406, is a potent Syk inhibitor with IC50 of 41 nM.

901119-35-5
DC1013 R788 disodium (Fostamatinib) Featured

R935788 (Fostamatinib disodium, R788) is a Syk inhibitor with IC50 of 41 nM.

1025687-58-4
DC9759 RO0921 Featured

RO0921 is a novel, potent SYK inhibitor.

1446790-62-0
DC10523 TAK-659 HCl Featured

TAK-659 hydrochloride is a potent, selective and orally available spleen tyrosine kinase (Syk) inhibitor with an IC50 of 3.2 nM.

1952251-28-3
DC28254 Lanraplenib monosuccinate

Lanraplenib monosuccinate (GS-9876 monosuccinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.

1800046-97-2
DC28255 Lanraplenib succinate

Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib succinate (GS-9876 succinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.

1800047-00-0
DC40367 Syk-IN-1

Syk-IN-1 (compound 4) is a potent Syk inhibitor, with an IC50 of 35 nM.

1491150-77-6
DC40848 SRX3207

SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor. SRX3207 possesses anti-tumor activity.

2254693-15-5
DC41092 Cerdulatinib hydrochloride

Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and JAK, with IC50s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK and Tyk2, JAK1, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies.

1369761-01-2
DC42006 Syk Kinase Peptide Substrate, Biotin labeled

Syk Kinase Peptide Substrate, Biotin labeled is a biotin-labled Syk kinase peptide substrate.

DC42007 Syk Kinase Peptide Substrate

Syk Kinase Peptide Substrate is a Syk kinase peptide substrate.

865778-47-8
DC42425 Syk-IN-4

Syk-IN-4 is a potent, selective and orally bioavailable SYK with an IC50 of 0.31 nM. SYK has emerged as a potential target for autoimmunity and hematological cancers.

Page 1 / Total 1 FirstPrevNextLastGoto